Current Barriers to Bedaquiline Access
Bedaquiline, a key drug for multidrug-resistant tuberculosis (MDR-TB), faces high costs and supply restrictions in low-income countries. Janssen's pricing exceeds $1,000 per course in many settings, while patents limit generic production until at least 2025 in key markets.[1] WHO-prequalified generics exist from companies like Macleods and Hetero, but distribution remains uneven due to tender processes and national procurement delays.
Generic Licensing and Voluntary Agreements
Janssen's 2015 Medicine Patent Pool (MPP) agreement allows generic manufacturers in 109 low- and middle-income countries to produce and sell bedaquiline at reduced costs, dropping prices to $300-$500 per course.[2] To expand access:
- Extend MPP licenses to more countries, including upper-middle-income ones like Brazil and South Africa.
- Encourage additional licensees; only a handful (e.g., Lupin, Cipla) currently participate.
Patent Challenges and Compulsory Licensing
Patents expire in India (2024) and parts of Africa soon, enabling broader generic entry.[3] Resource-limited governments can issue compulsory licenses under TRIPS flexibilities, as Thailand did for efavirenz. Advocacy groups like Médecins Sans Frontières (MSF) push for this:
- File patent oppositions at bodies like India's Patent Office.
- Use WTO's TRIPS waiver for COVID-19 as a model for TB drugs.
Pooled Procurement and Global Funds
Centralized buying cuts costs further:
- The Global Drug Facility (GDF) and Stop TB Partnership negotiate bulk deals, achieving $290 per course in high-burden countries like India and Pakistan.[4]
- Expand GDF's multi-source tenders to include more generics and increase funding from the Global Fund, which covers 80% of MDR-TB drugs in eligible nations.
Manufacturing Scale-Up and Technology Transfer
Boost local production:
- Transfer technology from Janssen to African/Asian firms via MPP, as done for pediatric formulations.
- Support WHO prequalification of new generics; 10+ are now listed, but scale-up lags in sub-Saharan Africa.[5]
Domestic Policies and Advocacy Strategies
Countries like South Africa and Uzbekistan improved access by:
- Mandating generics in national guidelines.
- Partnering with NGOs for bridging supply gaps.
Patient groups urge delinkage of R&D costs from pricing and push for open-source TB drug development to prevent future monopolies.
[1] DrugPatentWatch.com
[2] Medicine Patent Pool
[3] Drugs for Neglected Diseases initiative (DNDi)
[4] Stop TB Partnership
[5] WHO Prequalification List